Adeza Biomedical's FullTerm, The Fetal Fibronectin Test Available Through Quest Diagnostics Inc. Nationwide

SUNNYVALE, Calif.--(BUSINESS WIRE)--May 4, 2006--Adeza (NASDAQ:ADZA - News) today announced that Quest Diagnostics Incorporated (NYSE:DGX - News), the nation's leading provider of diagnostic testing, information and services, is offering reference laboratory service for Adeza's FullTerm(TM), The Fetal Fibronectin Test to physicians nationwide. Through its national network of laboratories and patient service centers, Quest Diagnostics will analyze fetal fibronectin test samples collected from patients by physicians' offices and clinics throughout the United States. Terms of the agreement were not disclosed.

Back to news